Anti-fungal compositions and methods for using same
View Patent ↗Provided are compounds, compositions, and methods for treatment of fungal infections. The compositions comprise the mannose disaccharide analog (2R,3S,4S,5S,6R)-2-((((3S,4R,5R)-4,5-dihydroxypiperidin-3-yl)methyl)thio)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol. Methods are also provided for the treatment of fungal infections comprising contacting the infected site with a therapeutically effective concentration of the present compound or compositions.
1 . A composition comprising a compound having the following structure Formula I):
including α and β diastereomers and/or pharmaceutically acceptable salts thereof in a pharmaceutical carrier, wherein the compound is present at a concentration of 5 micrograms/mL to 31.25 micrograms/mL; and a calcium salt present at a concentration of 5 mg/mL to 120 mg/mL.
2 . The composition of claim 1 , wherein the calcium salt is calcium chloride, calcium phosphate, calcium carbonate, calcium acetate, calcium gluconate, calcium lactate, calcium gluceptate or calcium glycerophosphate.
3 . The composition of claim 1 , wherein the calcium salt is CaCl 2 .
4 . The composition of claim 1 , wherein the compound of formula I is the only disaccharide present and wherein the composition is free of monosaccharides or trisaccharides.
5 . The composition of claim 1 , wherein the composition is suitable for topical application.
6 . The composition of claim 1 , wherein the compound is present at a concentration of 5 micrograms/ml to 25 micrograms/ml.
7 . The composition of claim 1 , wherein the composition is present as an ointment, paste, gel, liquid, solid, or aerosolized.
8 . A method of treating a fungal infection comprising administering to an individual in need of treatment, or contacting an infected area of the individual with, a composition of claim 1 , wherein treating consists of alleviation of acute or chronic signs and/or malfunctions associated with fungal infection and the fungal infection is associated with or caused by Candida, Aspergillus , or Trychophoton.
9 . The method of claim 8 , where administration comprises contacting an infected area of the individual.
10 . The method of claim 9 , wherein the compound is administered at a dosage of 0.05 to about 100 mg/kg of body weight per day.
11 . The method of claim 8 , wherein the infection is caused by one or more of Candida albicans, Candida guilliermondii, Candida glabrata, Candidia parapsilois, Candidia apicola, Candida tropicalis, Candida lustaniae, Candida krusei, Trychophoton rubrum, Trychophoton mentagrophytes, Trychophoton verrucosum , and Trychophoton tonsurans.